Don’t let the high cost of brand specialty asthma biologics stand between you and the treatment you need. We help eligible patients access Nucala (mepolizumab) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
The Nucala Prescription Assistance Program is a manufacturer-sponsored initiative that provides Nucala at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for severe asthma and other eosinophil-driven conditions in patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, pulmonology/allergy/rheumatology coordination, eosinophil count documentation, prior-authorization documentation, specialty pharmacy logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and annual re-certification — so you focus on your health, not paperwork.
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$4,400.00 | Save ~$4,330/dose |
| CVS Pharmacy | ~$4,500.00 | Save ~$4,430/dose |
| Walmart | ~$4,200.00 | Save ~$4,130/dose |
| Costco | ~$4,100.00 | Save ~$4,030/dose |
| Specialty Pharmacy | ~$4,200.00 | Save ~$4,130/dose |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
1 Medications
2 Medications
3 Medications
4+ Medications
The Patient Assistance Program is free to apply for and provides Nucala at no medication cost if approved. But the process involves detailed applications, prescriber coordination, eosinophil count documentation, prior-authorization documentation, specialty pharmacy logistics, and ongoing renewal management. Our $69.95/month service covers full advocacy.
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Nucala:
Still $4,000–$4,500 per month even with the best discount
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Nucala assistance.
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Nucala (mepolizumab) is a biologic medicine in the anti-interleukin-5 (IL-5) class used to treat several eosinophil-driven inflammatory conditions — severe eosinophilic asthma in patients 6 and older, eosinophilic granulomatosis with polyangiitis (EGPA) in adults, hypereosinophilic syndrome (HES), and chronic rhinosinusitis with nasal polyps. It is given as a subcutaneous injection every 4 weeks.
How Nucala Works:
Nucala is a monoclonal antibody that targets Interleukin-5 (IL-5), the primary regulator of eosinophil production and survival. In certain types of asthma and inflammatory conditions, overactive eosinophils accumulate in tissues and cause damage. By blocking IL-5 from connecting to its receptors, Nucala reduces eosinophil counts and dampens inflammation, leading to fewer asthma exacerbations and a reduced need for systemic corticosteroids.
Form and use:
This medication is administered as a subcutaneous injection once every four weeks. It is available in a 100 mg prefilled syringe or autoinjector for adults, while pediatric patients aged 6–11 receive a lower 40 mg dose. After receiving proper training, some patients may self-administer the injection at home. Nucala functions as a long-term controller and should never be used to treat acute asthma symptoms.
Generic availability:
As of 2026, there is no FDA-approved biosimilar version of Nucala available in the United States. Other biologic options that target the IL-5 pathway include Cinqair (administered intravenously) and Fasenra (a subcutaneous injection). The choice between these treatments depends on a patient’s specific diagnosis, treatment history, and preference for how frequently they receive their medication.
Warnings:
Nucala carries warnings for hypersensitivity reactions, including anaphylaxis, and the potential reactivation of the herpes zoster (shingles) virus. Patients with parasitic infections should be treated before starting therapy, and live vaccines should be avoided while using the medication. It is essential to remember that Nucala is not a rescue medication and will not work for acute asthma attacks or status asthmaticus.
The average retail price runs approximately $4,000–$4,500 per monthly dose. Annual costs commonly reach $50,000+. Through AffordMyPrescriptions, qualifying patients receive Nucala at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Nucala targets IL-5, a key cytokine driving eosinophilic inflammation. Other anti-IL-5 biologics include reslizumab (Cinqair, IV monthly) and benralizumab (Fasenra, SC every 4 weeks initially, then every 8 weeks). Other severe asthma biologics target different mechanisms — anti-IgE (Xolair), anti-IL-4Rα (Dupixent), and anti-TSLP (Tezspire). Whether Nucala or a different biologic is a better fit depends on your phenotype (eosinophilic vs. allergic vs. mixed), eosinophil count, and IgE level.
Yes, for severe eosinophilic asthma. Patients are typically required to have eosinophil counts ≥150 cells/μL at initiation (or ≥300 cells/μL within the past 12 months) to qualify for Nucala in severe eosinophilic asthma. Other indications (EGPA, HES, nasal polyps) have different eligibility criteria.
Yes, for many patients. Nucala is available as a prefilled autoinjector or syringe for self-administration after training by a healthcare provider. Initial doses are typically given in a healthcare setting, but ongoing every-4-week dosing can usually be done at home.
Yes. Medicare Part D beneficiaries can typically qualify for Nucala Patient Assistance, especially if you face specialty-tier copays you cannot afford. The manufacturer’s commercial copay savings program is reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria.
If your initial application is denied, we explore alternatives — the manufacturer’s copay savings program if you have commercial insurance, independent foundations such as the Asthma and Allergy Foundation of America, American Lung Association, PAN Foundation, or HealthWell Foundation, or asking your prescriber whether a different anti-IL-5 biologic (Fasenra, Cinqair) or another severe asthma biologic on a more accessible assistance pathway would be appropriate. If we cannot find a path, you will not be charged our service fee.
If you are struggling with the high cost of Nucala, our team may be able to help you access assistance programs designed to make brand specialty severe asthma biologics affordable. Check your eligibility today.
Start free by filling out a simple online form.
Our specialist will contact you for a quick welcome call.
Our team handles everything, so you can focus on your health.